Completed PHASE2 INTERVENTIONAL 1-arm NCT02390934

Efficacy of Radium 223 in Radioactive Iodine Refractory Bone Metastases From Differentiated Thyroid Cancer (RAD-THYR)

Single Arm Phase II Trial Evaluating the Efficacy of Radium 223 in Radioactive Iodine Refractory Bone Metastases From Differentiated Thyroid Cancer

Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Conditions Thyroid Cancer

Interventions Radium 223

Updated 7 times since 2017 Last updated: Jun 7, 2019 Started: Oct 1, 2014 Primary completion: Apr 2, 2019 Completion: Apr 2, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Thyroid Cancer and is currently completed. Gustave Roussy, Cancer Campus, Grand Paris leads this study, which shows 7 recorded versions since 2014 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jul 2019 — Jan 2021 [monthly]

Completed PHASE2

Status: Unknown Status → Completed
Jun 2019 — Jul 2019 [monthly]

Unknown Status PHASE2

Status: Recruiting → Unknown Status

▶ Show 2 earlier versions

Jun 2018 — Jun 2019 [monthly]

Recruiting PHASE2
Jan 2017 — Jun 2018 [monthly]

Recruiting PHASE2

First recorded

Oct 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Gustave Roussy, Cancer Campus, Grand Paris

Data source: Gustave Roussy, Cancer Campus, Grand Paris

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Villejuif, France